Printed From BioPortfolio.com
FDA approves new indication for Gilotrif in EGFR mutation-positive NSCLC
10:09 EST 17 Jan 2018 | European Pharmaceutical Review
The FDA has approved a supplemental New Drug Application for Gilotrif for the first-line treatment of patients with metastatic non-small cell lung cancer...
Original Article: FDA approves new indication for Gilotrif in EGFR mutation-positive NSCLC
